302 related articles for article (PubMed ID: 9187600)
1. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
Lugo G; Castañeda-Hernández G
Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
[TBL] [Abstract][Full Text] [Related]
2. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
[TBL] [Abstract][Full Text] [Related]
3. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis.
Lugo-Goytia G; Castañeda-Hernández G
Ann Pharmacother; 2000 Dec; 34(12):1389-94. PubMed ID: 11144694
[TBL] [Abstract][Full Text] [Related]
4. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.
Marsot A; Guilhaumou R; Riff C; Blin O
Clin Pharmacokinet; 2017 Feb; 56(2):127-138. PubMed ID: 27324191
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
[TBL] [Abstract][Full Text] [Related]
8. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize
Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443
[TBL] [Abstract][Full Text] [Related]
9. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
[TBL] [Abstract][Full Text] [Related]
10. Estimation of once-daily amikacin dose in critically ill adults.
Šíma M; Hartinger J; Cikánková T; Slanař O
J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
Burdet C; Pajot O; Couffignal C; Armand-Lefèvre L; Foucrier A; Laouénan C; Wolff M; Massias L; Mentré F
Eur J Clin Pharmacol; 2015 Jan; 71(1):75-83. PubMed ID: 25327505
[TBL] [Abstract][Full Text] [Related]
14. Aminoglycoside volume of distribution and illness severity in critically ill septic patients.
Marik PE
Anaesth Intensive Care; 1993 Apr; 21(2):172-3. PubMed ID: 8517507
[TBL] [Abstract][Full Text] [Related]
15. Physiologic response of stress and aminoglycoside clearance in critically ill patients.
Tholl DA; Shikuma LR; Miller TQ; Woodward JM; Cerra FB; Zaske DE
Crit Care Med; 1993 Feb; 21(2):248-51. PubMed ID: 8428477
[TBL] [Abstract][Full Text] [Related]
16. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
[TBL] [Abstract][Full Text] [Related]
17. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.
D'Arcy DM; Casey E; Gowing CM; Donnelly MB; Corrigan OI
BMC Pharmacol Toxicol; 2012 Nov; 13():14. PubMed ID: 23136834
[TBL] [Abstract][Full Text] [Related]
18. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
[TBL] [Abstract][Full Text] [Related]
19. Amikacin population pharmacokinetics among paediatric burn patients.
Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
